Advancing antisolvent membrane crystallisation

推进反溶剂膜结晶

• 批准号: 2880828
• 金额: --
• 依托单位: CRANFIELD UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2880828
• 关键词: Advancing; antisolvent; membrane; crystallisation

Reverse anti-solvent membrane crystallisation can produce the submicron sized drug particles required for long-acting injectable formulations through the unparalleled control of solvent mixing that is both precise and scalable. This disruptive technology mitigates the solid-state changes and particle size variability associated with historic drug production approaches to catalyse the development and manufacture of long-acting injectable medicines that are critically important to a wide range of treatments. The PhD candidate will work closely with the industrial sponsor (GlaxoSmithKline, GSK) and academic partners to develop this technology, including secondment into GSK, which may include on-site testing of the developed membrane crystallisation process at GSKs campus

反溶剂膜结晶可以通过精确且可扩展的无与伦比的溶剂混合控制来生产长效注射制剂所需的亚微米大小的药物颗粒。这种颠覆性技术减轻了与历史药物生产方法相关的固态变化和粒径变异性，以催化对多种治疗至关重要的长效注射药物的开发和制造。博士候选人将与工业赞助商（葛兰素史克、葛兰素史克）和学术合作伙伴密切合作，开发这项技术，包括借调到葛兰素史克，其中可能包括在葛兰素史克园区对开发的膜结晶工艺进行现场测试